Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Xenetic Biosciences, Inc. (XBIO)

Xenetic releases updated investor deck for pending Santersus share exchange

Neutral Impact 4 of 5 m&a Written later

Xenetic Biosciences furnished an updated September 2026 investor presentation tied to its pending share exchange with Santersus AG, first announced September 16, 2026. The presentation shows Santersus shareholders expected to own about 85% of the combined company and Xenetic stockholders about 15%, subject to adjustment, with closing expected in the fourth quarter of 2026.

Key points

  • Transaction valuation shown as $120 million for Santersus and $21 million for Xenetic, or $141 million in total, under the Share Exchange Agreement dated September 14, 2026
  • Closing is expected in the fourth quarter of 2026 and is subject to approval by Xenetic stockholders
  • The combined company is expected to trade on Nasdaq under the ticker SNTS

The filing

CompanyXenetic Biosciences, Inc. (XBIO)
Form8-K, current report
Filed with the SECSep 23, 2026, 5:20 PM ET
Accession number0001683168-26-007340

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.